PRFN.SW down 8.12% to CHF0.0362 02 Jan 2026 after hours: high volume trade cue
PRFN.SW traded down 8.12% to CHF0.0362 in after-hours trading on 02 Jan 2026 on the SIX, driven by a surge to 2,937,350 shares, roughly 3.42 times average volume. PRFN.SW is the most active name in today’s microcap list, and the move highlights short-term seller pressure against thin liquidity. Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical firm based in Lausanne, shows low market capitalisation data and mixed classification in exchange records; we unpack the price action, ratios and a model forecast from our AI-powered market analysis platform.
Price action and trading flow
PRFN.SW closed at CHF0.0362 after hours, down CHF0.0032 or 8.12% from a previous close of CHF0.0394; the intraday range was CHF0.0352 to CHF0.0400. Volume spiked to 2,937,350 shares versus an average volume of 859,130, giving a relative volume of 3.4189 and signalling outsized activity on the SIX market in Switzerland.
Fundamentals and valuation
Kinarus Therapeutics Holding AG reports EPS of CHF-0.001 and a negative price/earnings context with PE around -36.20 on trailing EPS, reflecting losses at a small scale. The stock sits well below its 50-day average of CHF0.072748 and 200-day average of CHF0.074202. Enterprise value is reported at CHF305,000 and market cap data is not available, underlining microcap status and limited free float.
Liquidity, volatility and trading risk
The stock’s year high is CHF0.126 and year low is CHF0.034; the current price is 6.47% above the year low but 71.30% below the 52-week high. Average daily volume is modest at 859,130 but today’s 2,937,350 shares show episodic liquidity spikes; such swings increase execution risk and widen spreads for larger orders.
Sector context and data consistency
Company profile describes Kinarus Therapeutics as a clinical-stage biopharmaceutical group based in Lausanne, Switzerland, yet exchange metadata classifies it under Industrials. Sector dispersion and the small firm profile mean peer comparisons are imperfect, but healthcare and small-cap biotech trends remain the relevant backdrop for product, R&D and funding catalysts.
Meyka AI grade and model forecast
Meyka AI rates PRFN.SW with a score out of 100: 67.07 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects CHF0.065 as a 12-month base scenario, implying an upside of 79.60% from the current CHF0.0362. Forecasts are model-based projections and not guarantees.
Catalysts and downside risks
Near-term catalysts for PRFN.SW would be clinical updates for KIN001, financing announcements, or licensing deals; there is no scheduled earnings release in the feed. Key risks are continued dilution, limited cash per share (CHF0.000736), negative operating cash flow per share (CHF-0.002131), and classification/visibility issues on the exchange that can deter institutional interest.
Final Thoughts
PRFN.SW stock is trading as a high‑activity microcap on the SIX after hours, with today’s 8.12% decline to CHF0.0362 accompanied by a volume surge to 2,937,350 shares. The balance of data shows a firm trading well below both the 50-day (CHF0.072748) and 200-day (CHF0.074202) averages, tight cash metrics, and negative EPS of CHF-0.001, all consistent with heightened short-term volatility. Meyka AI rates PRFN.SW 67.07/100 (Grade B, HOLD), reflecting mixed signals across sector, growth and key metrics. Meyka AI’s forecast model projects CHF0.065 within 12 months, implying a model-based upside of 79.60% versus the current price of CHF0.0362; this projection is not a guarantee. For active traders, today’s volume spike creates a short-term trade cue but execution risk is high given thin free float. Long-term investors should await clinical or financing clarity and monitor liquidity, announced milestones, and any reclassification or corporate updates on the SIX before repositioning.
FAQs
The after-hours decline to CHF0.0362 followed heavy trading: 2,937,350 shares versus average 859,130. The move reflects short-term selling and thin liquidity rather than a published earnings release; no earnings announcement is listed in the data feed.
Meyka AI rates PRFN.SW 67.07/100, Grade B with a HOLD suggestion. The grade factors in benchmark and sector comparisons, financial growth, key metrics and analyst consensus; it is informational and not investment advice.
Meyka AI’s forecast model projects CHF0.065 over 12 months from CHF0.0362 today, implying 79.60% upside. Forecasts are model-based projections and not guarantees; liquidity and clinical catalysts remain key.
High risk: the stock has limited market-cap data, low cash per share (CHF0.000736), negative operating cash flow per share (CHF-0.002131), and episodic volume spikes. Expect wide spreads and execution risk on the SIX.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
